# US 2019/0169182 A1 · Novel therapeutic agents for the treatment of hbv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169182 A1
- Document ID: US20190169182A1
- Status: Published application
- Kind: A1
- Application number: 16/269,824
- Filed: 2019-02-07
- Published: 2019-06-06
- Earliest claimed: 2016-07-29
- Assignees: Newave Pharmaceutical Inc.
- Applicants: Newave Pharmaceutical Inc.
- Inventors: Yi Chen; Yan Lou
- Web page: https://patentgrep.com/patent/US20190169182A1

## CPC

- C07D 455/06: containing benzo [a] quinolizine ring systems
- A61P 31/20: for DNA viruses
- C07D 471/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure includes compounds of Formula (I) wherein Z1, Z2, Z3, X, R1, R2, R3, R4, R5, R6, and R7 are defined herein. Also disclosed is a method for treating HBV infection.

## Claims

### Claim 1

A compound or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 2 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 3 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 4 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 5 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 6 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 7 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 8 (depends on 1)

The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is

### Claim 9

A compound of Formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer of said compound of Formula (I) or N-oxide thereof:
wherein
R1 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, cyano, —(CH2)pRa, —ORa, —SRa, —NH(CH2)pRa, —C(O)Ra, —S(O)Ra, —SO2Ra, —C(O)ORa, —OC(O)Ra, —NRbRc, —P(O)RbRc, —C(O)N(Rb)Rc, —N(Rb)C(O)Rc, —SO2N(Rb)Rc, or —N(Rb)SO2Rc, in which said alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionally subsitiuted with one or more Rd;
R5 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, —(CH2)pRa, —C(O)Ra, —S(O)Ra, —SO2Ra, —C(O)ORa, —C(O)N(Rb)Rc, —SO2N(Rb)Rc, in which said alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionally subsitiuted with one or more Rd;
each of p, and q, independently, is 0, 1, 2, 3, 4, 5, 6, 7, or 8; and
Ra, Rb, Rc and Rd, independently, is H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl.

### Claim 10 (depends on 9)

The compound according to claim 9 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R1 is H or alkyl optionally subsitiuted with one or more D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl.

### Claim 11 (depends on 10)

The compound according to claim 10 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R5 is H or alkyl optionally subsitiuted with one or more D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl.

### Claim 12 (depends on 11)

The compound according to claim 11 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R1 is H or alkyl optionally subsitiuted with one or more D, alkyl, halo, alkoxy, alkoxyalkyl, or haloalkyl.

### Claim 13 (depends on 12)

The compound according to claim 12 or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R5 is H or alkyl optionally subsitiuted with one or more D, alkyl, halo, alkoxy, alkoxyalkyl, haloalkyl.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 15 (depends on 1)

A method of treatment or prophylaxis of HBV, comprising administering to a subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof.
